Kineret

( ARTG ) KINERET (anakinra) is indicated: -for the treatment of active adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more other Disease Modifying Anti Rheumatic Drugs (DMARDs).‍‍‍‍‍‍​​​‍​​​​​​ KINERET should be given in combination with methotrexate. - in adult and paediatric patients aged 8 months and older with a body weight of 10 kg or above for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) including Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), Muckle-Wells Syndrome (MWS), and Familial Cold Autoinflammatory Syndrome (FCAS). - for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years and above who have failed to respond adequately to non-biological DMARDs